Related Experiment Videos
Pefloxacin in adriamycin induced nephrotic syndrome in the rat
Z Korzets1, A Pomeranz, E Golan
1Department of Nephrology, Meir General Hospital, Kfar Saba, Israel.
Background:
Pefloxacin, a fluorinated 4-quinolone, has recently been advocated as a first-line treatment for minimal-change nephropathy (MCN) or focal segmental glomerulosclerosis (FSGS). To further evaluate this issue we have utilized an animal model resembling human MCN, namely adriamycin-induced nephrotic syndrome in Wistar male rats.
Methods:
Adriamycin at a dose of 7 mg/kg was injected intravenously to all rats at day zero. Rats were divided into two groups: group A (n = 20) given only water served as the control group while group B (n = 19) was administered pefloxacin at 150 mg/kg. At days 7, 14, 21 and 28, the rats were placed in metabolic cages and daily proteinuria determined.
Results:
The nephrotic syndrome developed in all rats within 7 days of adriamycin administration. At day 7, proteinuria in group B was 173 +/- 78 vs 423 +/- 626 mg/day in group A, P < 0.02, but thereafter at days 14, 21 and 28, no significant difference in urinary protein excretion was noted.
Conclusions:
These results suggest that in this animal model of NS mimicking human MCN, pefloxacin's antiproteinuric effect is only of a mild and transitory nature. In view of the above data and the overall results in human patients (detailed herein), the use of pefloxacin as definitive treatment of the NS cannot be recommended.
Insights
Pefloxacin showed a mild, temporary reduction in proteinuria in an adriamycin-induced nephrotic syndrome rat model. These findings do not support using pefloxacin for minimal-change nephropathy or focal segmental glomerulosclerosis treatment.
Area of Science:
- Nephrology
- Pharmacology
Background:
- Pefloxacin, a fluoroquinolone, is considered for minimal-change nephropathy (MCN) and focal segmental glomerulosclerosis (FSGS).
- An adriamycin-induced nephrotic syndrome rat model was used to investigate pefloxacin's efficacy.
Purpose of the Study:
- To evaluate the antiproteinuric effect of pefloxacin in an animal model of MCN/FSGS.
Main Methods:
- Wistar male rats received adriamycin (7 mg/kg) to induce nephrotic syndrome.
- Group A (control) received water, while Group B (n=19) received pefloxacin (150 mg/kg).
- Daily proteinuria was measured on days 7, 14, 21, and 28.
Main Results:
- Nephrotic syndrome developed in all rats within 7 days.
- On day 7, pefloxacin treatment significantly reduced proteinuria (173 mg/day vs. 423 mg/day in controls, P < 0.02).
- No significant difference in proteinuria was observed between groups on days 14, 21, and 28.
Conclusions:
- Pefloxacin demonstrated a mild and transient antiproteinuric effect in this MCN/FSGS rat model.
- The study does not support pefloxacin as a definitive treatment for nephrotic syndrome.
- Results align with human patient data, questioning pefloxacin's therapeutic role.